Loading…
avatar for Martin Murphy

Martin Murphy

Chief Executive Officer of Syncona Partners LLP

Martin is the Chief Executive Officer of Syncona Partners LLP.  Previously, he was a Partner at MVM Life Science Partners LLP, a leading venture capital company focused on life science and healthcare investments. During his time at MVM, Martin was a member of the Management and Investment Committees and led MVM’s European operations.  He was involved in a number of successful investments including PregLem SA (sold to Gedeon Richter), Momenta Pharmaceuticals, Inc, (NASDAQ:  MNTA), Healthcare Brands International (sold to Meda AB) and Heptares Therapeutics Ltd. Before MVM, Martin had roles with 3i Group plc and McKinsey & Company. Martin has a PhD in Biochemistry from Cambridge University. Syncona Partners is an independent subsidiary of the Wellcome Trust who invested the initial £200m capitalisation.  Syncona Partners provides financial resources to individuals and companies to advance the Wellcome Trust’s vision of achieving extraordinary improvements in human and animal health by supporting the brightest minds in biomedical research and the medical humanities.

My Speakers Sessions

Tuesday, March 5
 

4:00pm